The Promise of Anti-BCMA CAR T-Cell Therapy in MM

Anti-BCMA CAR T-cell therapy in myeloma: updates from ASH 2020Подробнее

The promise of CAR T-cell therapyПодробнее

Ide-cel (formerly bb2121) anti-BCMA CAR T-cell therapy in relapsed/refractory MMПодробнее

The future of anti-BCMA CAR T-cell therapy in myelomaПодробнее

Promise of GPRC5D-targeted CAR-T therapies in multiple myelomaПодробнее

Biallelic Loss of BCMA Triggers Resistance to Anti-BCMA CAR T Cell Therapy in Multiple MyelomaПодробнее

Anti-BCMA CAR T cell therapy for multiple myelomaПодробнее

Anti-BCMA CAR T-cells for MM: durable clinical responses with ide-cel (formerly bb2121)Подробнее

Anti-BCMA CAR T-cell therapy for multiple myeloma: latest studiesПодробнее

Optimizing the Use of Anti-BCMA Therapy in MMПодробнее

Clinical activity seen with anti-BCMA CAR T-Cell therapy for heavily pre-treated multiple myelomaПодробнее

Where are we on anti-BCMA CAR T-cell therapies for MM?Подробнее

Phase 1 Study PHE885 BCMA-Directed CAR-T Cell Therapy for RRMM | Adam Sperling, MD, PhD | ASCO 2023Подробнее

CAR T-Cells Multiple Myeloma: Adam Sperling, MD, PhDПодробнее

Multiple myeloma: Anti-BCMA BiTE AMG 701 shows preclinical promiseПодробнее

The promise of CAR-T cells for patients with triple-class exposed myelomaПодробнее

Anti-BCMA CAR T-cells in myeloma: what data do we have so far?Подробнее

CAR T-cells: targeting BCMAПодробнее

David Siegel, MD, discusses anti-BCMA CAR-T cell therapy for multiple myeloma patientsПодробнее